These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31784033)

  • 1. The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients.
    Rallidis LS
    Atherosclerosis; 2020 Jan; 292():231-233. PubMed ID: 31784033
    [No Abstract]   [Full Text] [Related]  

  • 2. New concepts in the management of dyslipidaemiaa.
    Gencer B; Rodondi N; Mach F
    Swiss Med Wkly; 2016; 146():w14378. PubMed ID: 27878791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
    Gebauer K; Reinecke H
    Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Critical review of the ESC Guidelines 2019 for the management of dyslipidaemias in 10 key-messages].
    Toussaint K; Brückner C
    MMW Fortschr Med; 2020 May; 162(10):45-48. PubMed ID: 32447677
    [No Abstract]   [Full Text] [Related]  

  • 7. [ECS guidelines 2016 - dyslipidaemias].
    Sinning D; Landmesser U
    Herz; 2016 Dec; 41(8):671-676. PubMed ID: 27844136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
    Mach F; Baigent C; Catapano AL; Koskinas KC; Casula M; Badimon L; Chapman MJ; De Backer GG; Delgado V; Ference BA; Graham IM; Halliday A; Landmesser U; Mihaylova B; Pedersen TR; Riccardi G; Richter DJ; Sabatine MS; Taskinen MR; Tokgozoglu L; Wiklund O;
    Eur Heart J; 2020 Jan; 41(1):111-188. PubMed ID: 31504418
    [No Abstract]   [Full Text] [Related]  

  • 9. [2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: What is new?].
    Kayıkçıoğlu M; Tokgözoğlu L
    Turk Kardiyol Dern Ars; 2017 Mar; 45(2):109-112. PubMed ID: 28424431
    [No Abstract]   [Full Text] [Related]  

  • 10. Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
    Gencer B; Koskinas KC; Räber L; Karagiannis A; Nanchen D; Auer R; Carballo D; Carballo S; Klingenberg R; Heg D; Matter CM; Lüscher TF; Rodondi N; Mach F; Windecker S
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
    Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
    Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
    Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
    Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia.
    Papademetriou V; Stavropoulos K; Papadopoulos C; Koutsampasopoulos K; Dimitriadis K; Tsioufis K
    Curr Pharm Des; 2018; 24(31):3647-3653. PubMed ID: 30317985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL.
    Rallidis LS; Kiouri E; Katsimardos A; Kotakos C
    Atherosclerosis; 2018 Aug; 275():262-264. PubMed ID: 29980053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

  • 18. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
    Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
    Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
    ; Reiner Z; Catapano AL; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegria E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs R; Kjekshus J; Filardi PP; Riccardi G; Storey RF; Wood D;
    Eur Heart J; 2011 Jul; 32(14):1769-818. PubMed ID: 21712404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A perspective to lipid lowering therapy after ESC/EAS guidelines for the management of dyslipidaemias and the European guidelines on cardiovascular disease prevention in clinical practice].
    Ural D
    Turk Kardiyol Dern Ars; 2012 Jun; 40(4):293-7. PubMed ID: 22951844
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.